Bioarchitech is kicking off 2025 with a major milestone—the filing of another UK patent application for our cutting-edge RNA technology, BA-R166.

What is BA-R166?

This innovative dual-action RNA immunotherapy is administered prior to surgery and is designed to turn tumours into their own vaccine in-situ through two important steps:
1. Cell lysis: BA-R166 effectively ‘detonates’ cancer cells from within, causing them to release tumour associated neoantigens.
2. Immune activation: Generates danger signals to activate the immune system and make sure the released neoantigens are effectively presented to the immune system.

With a rapid mechanism of action of just three days, BA-R166 helps activate anti-tumour immunity prior to surgery.  Patients then carry on with treatment as normal, their tumour is removed and systemic anti-tumour immunity is left behind to fight relapse.

What truly sets BA-R166 apart is its potential to be a cost-effective, off-the-shelf, personalised neoantigen therapy—suitable for all patients prior to surgery